CVS Health sticks to 2026 targets after robust Q4 beat
CVS Health beat Q4 estimates with adjusted EPS of $1.09 and revenue of $105.69 billion, and reaffirmed its 2026 guidance of $7.00–$7.20 per share and at least $400 billion in revenue. Management cited headwinds from exiting ACA exchanges and lower drug prices under new pricing deals, while growth is expected from Caremark and improving Aetna margins, Oak Street Health, and the Rite Aid prescription integration.